Whereas reduced-count MBL not often progresses to CLL, large-rely MBL progresses to CLL requiring therapy in a amount of one% to 2% every year. Superior-rely MBL is distinguished from Rai 0 CLL based upon if the B-cell rely is higher than or below five × 109/L. While people today with both of those high-count MBL and CLL Rai stage 0 are at improve